Page last updated: 2024-08-16

resveratrol and Friedreich Ataxia

resveratrol has been researched along with Friedreich Ataxia in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aubry, L; Bayot, A; Boza-Moran, MG; Forêt, B; Georges, P; Gide, J; Martinat, C; Pêche, GA; Peschanski, M; Rustin, P	1
Gottesfeld, JM	1
Churchyard, A; Corben, LA; Croft, KD; Delatycki, MB; Evans-Galea, MV; Lee, CY; Lee, KJ; Lockhart, PJ; Mori, TA; Peverill, RE; Praschberger, M; Rance, G; Ryan, MM; Sarsero, JP; Scheiber-Mojdehkar, B; Stephenson, SE; Stockley, C; Sturm, B; Tai, G; Vogel, AP; Yiu, EM	1

Reviews

1 review(s) available for resveratrol and Friedreich Ataxia

Article	Year
Molecular Mechanisms and Therapeutics for the GAA·TTC Expansion Disease Friedreich Ataxia. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2019, Volume: 16, Issue:4 Topics: Animals; Drug Delivery Systems; Friedreich Ataxia; Gene Silencing; Gene Transfer Techniques; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Promoter Regions, Genetic; Resveratrol; Trinucleotide Repeat Expansion	2019

Article

Year

Molecular Mechanisms and Therapeutics for the GAA·TTC Expansion Disease Friedreich Ataxia.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2019, Volume: 16, Issue:4

Topics: Animals; Drug Delivery Systems; Friedreich Ataxia; Gene Silencing; Gene Transfer Techniques; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Promoter Regions, Genetic; Resveratrol; Trinucleotide Repeat Expansion

2019

Trials

1 trial(s) available for resveratrol and Friedreich Ataxia

Article	Year
An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. Journal of neurology, 2015, Volume: 262, Issue:5 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Antioxidants; Deoxyguanosine; F2-Isoprostanes; Female; Fourier Analysis; Frataxin; Friedreich Ataxia; Humans; Iron-Binding Proteins; Leukocytes, Mononuclear; Male; Middle Aged; Resveratrol; RNA, Messenger; Stilbenes; Treatment Outcome; Young Adult	2015

Article

Year

An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.

Journal of neurology, 2015, Volume: 262, Issue:5

Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Antioxidants; Deoxyguanosine; F2-Isoprostanes; Female; Fourier Analysis; Frataxin; Friedreich Ataxia; Humans; Iron-Binding Proteins; Leukocytes, Mononuclear; Male; Middle Aged; Resveratrol; RNA, Messenger; Stilbenes; Treatment Outcome; Young Adult

2015

Other Studies

1 other study(ies) available for resveratrol and Friedreich Ataxia

Article	Year
Induced pluripotent stem cells-derived neurons from patients with Friedreich ataxia exhibit differential sensitivity to resveratrol and nicotinamide. Scientific reports, 2019, 10-10, Volume: 9, Issue:1 Topics: Apoptosis; Cell Survival; Cells, Cultured; Drug Design; Fibroblasts; Frataxin; Friedreich Ataxia; Gene Expression Profiling; Humans; Induced Pluripotent Stem Cells; Iron-Binding Proteins; Karyotyping; Neurons; Niacinamide; Phenotype; Resveratrol; Translational Research, Biomedical	2019

Article

Year

Induced pluripotent stem cells-derived neurons from patients with Friedreich ataxia exhibit differential sensitivity to resveratrol and nicotinamide.

Scientific reports, 2019, 10-10, Volume: 9, Issue:1

Topics: Apoptosis; Cell Survival; Cells, Cultured; Drug Design; Fibroblasts; Frataxin; Friedreich Ataxia; Gene Expression Profiling; Humans; Induced Pluripotent Stem Cells; Iron-Binding Proteins; Karyotyping; Neurons; Niacinamide; Phenotype; Resveratrol; Translational Research, Biomedical

2019